Dysphonia News and Research

RSS

Botox for asthma

Botox, or botulinum toxin type A, which is best-known for smoothing away facial wrinkles is to be tested as an asthma treatment at Melbourne's Monash University. A recent survey by the university found that about half of severe asthmatics suffer problems with their voice box as well as their lungs. The problems were similar to vocal cord dysphonia – or loss of voice through overuse – a condition which Botox is frequently used to fix.

29 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Fatigue and poor health may have major impact on patients with functional dysphonia

Fatigue and poor health, anxiety and depression may have a major impact on patients with functional dysphonia (FD), leading to time off work, reduced activity, and social withdrawal, all of which could further perpetuate and/or cause anxiety, low mood, fatigue and reduced voice use, according to new research published in the June 2011 issue of Otolaryngology - Head and Neck Surgery.

2 Jun 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Novartis' TOBI Podhaler receives Health Canada NOC for Pa treatment in CF patients

Novartis Canada announced today that it has received Health Canada Notice of Compliance for TOBI Podhaler, a fast and convenient inhaled therapy for cystic fibrosis patients aged six and over.

6 Apr 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

Voice disorders are not benign nuisances that go away

Two-thirds of Americans with voice problems don't seek medical care either because they don't know treatment is available or because they think the problem will just go away, according to a new study conducted at the Duke Voice Care Center.

21 Sep 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

AAO-HNSF to issue the first guideline for helping physicians manage dysphonia

The American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) will issue the first--and only--national clinical practice guideline to help healthcare practitioners identify and manage patients with hoarseness, also known as dysphonia. The guideline emphasizes evidence-based management of hoarseness by clinicians, and educates patients on the prevalence of this common vocal health issue.

1 Sep 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009

New voice care center

UT Southwestern Medical Center has gathered a team of specially trained physicians and therapists to launch a new center for voice care dedicated to disorders of the voice and larynx.

24 Nov 2008

Surgical technique provides the first permanent solution to treating vocal-cord spasms

The first large, long-term study of patients who had surgery to control vocal-cord spasms showed excellent results in the majority of cases, reports new UCLA research presented May 14 at the 126th Annual Meeting of the American Laryngological Association.

15 May 2005

New use of Botox helps voice disorders

An injection that’s best known for smoothing wrinkles also helps restore the voices — and the confidence — of people with a voice disorder caused by spasms in their vocal cord muscles, a new University of Michigan study finds.

24 Apr 2004